Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study

被引:67
作者
Barsoum, Michel K. [1 ]
Heit, John A. [1 ,2 ]
Ashrani, Aneel A. [2 ]
Leibson, Cynthia L. [3 ]
Petterson, Tanya M. [4 ]
Bailey, Kent R. [4 ]
机构
[1] Mayo Clin, Coll Med, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Dept Internal Med, Div Hematol, Rochester, MN 55905 USA
[3] Mayo Clin, Coll Med, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN 55905 USA
[4] Mayo Clin, Coll Med, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Venous thromboembolism; Deep vein thrombosis; Pulmonary embolism; Progestin; Epidemiology; HORMONE REPLACEMENT THERAPY; DEEP-VEIN THROMBOSIS; ORAL-CONTRACEPTIVES; PULMONARY-EMBOLISM; USERS; WOMEN; NORGESTIMATE; ESTROGEN; DISEASE;
D O I
10.1016/j.thromres.2010.08.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Because the risk of venous thromboembolism (VTE) associated with progestin is uncertain, we tested oral contraceptives, estrogen and progestin as independent VTE risk factors. Materials and Methods: Using longitudinal, population-based Rochester Epidemiology Project resources, we identified all Olmsted County, MN women with objectively-diagnosed incident VTE over the 13-year period, 1988-2000 (n = 726) and one to two Olmsted County women per case matched on age, event year and duration of prior medical history (n = 830), and reviewed their complete medical history in the community for previously-identified VTE risk factors (i.e., hospitalization with or without surgery, nursing home confinement, trauma/fracture, leg paresis, active cancer, varicose veins and pregnancy/postpartum), and oral contraceptive, oral estrogen, and oral or injectable progestin exposure. Using conditional logistic regression we tested these hormone exposures as VTE risk factors, both unadjusted and after adjusting for previously-identified VTE risk factors. Results: In unadjusted models, oral contraceptives, progestin alone, and estrogen plus progestin were significantly associated with VTE. Individually adjusting for body mass index (BMI) and previously-identified VTE risk factors, these effects remained essentially unchanged except that progestin alone was not associated with VTE after adjusting for active cancer. Considering only case-control pairs without active cancer, progestin alone was positively but non-significantly associated with VTE (OR = 2.49; p = 0.16). Adjusting for BMI and previously-identified VTE risk factors including active cancer, oral contraceptives, estrogen alone, and progestin with or without estrogen were significantly associated with VTE. Conclusions: Oral contraceptives, estrogen alone, estrogen plus progestin, and progestin with or without estrogen are independent VTE risk factors. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:373 / 378
页数:6
相关论文
共 32 条
[1]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[2]  
CURB D, 2006, ARCH INTERN MED, P166
[3]   Estrogen plus progestin and risk of venous thrombosis [J].
Cushman, M ;
Kuller, LH ;
Prentice, R ;
Rodabough, RJ ;
Psaty, BM ;
Stafford, RS ;
Sidney, S ;
Rosendaal, FR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (13) :1573-1580
[4]   Risk of venous thromboembolism in users of hormone replacement therapy [J].
Daly, E ;
Vessey, MP ;
Hawkins, MN ;
Carson, JL ;
Gough, P ;
Marsh, S .
LANCET, 1996, 348 (9033) :977-980
[5]   Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study [J].
Douketis, JD ;
Julian, JA ;
Kearon, C ;
Anderson, DR ;
Crowther, MA ;
Bates, SM ;
Barone, M ;
Piovella, F ;
Turpie, AG ;
Middeldorp, S ;
Nguyen, PV ;
Prandoni, P ;
Wells, PS ;
Kovacs, MJ ;
Macgillavry, MR ;
Costantini, L ;
Ginsberg, JS .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (05) :943-948
[6]  
FARLEY TMM, 1995, LANCET, V346, P1582
[7]   Postmenopausal hormone therapy increases risk for venous thromboembolic disease - The heart and estrogen/progestin replacement study [J].
Grady, D ;
Wenger, NK ;
Herrington, D ;
Khan, S ;
Furberg, C ;
Hunninghake, D ;
Vittinghoff, E ;
Hulley, S .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (09) :689-+
[8]   Prospective study of exogenous hormones and risk of pulmonary embolism in women [J].
Grodstein, F ;
Stampfer, MJ ;
Goldhaber, SZ ;
Manson, JE ;
Colditz, GA ;
Speizer, FE ;
Willett, WC ;
Hennekens, CH .
LANCET, 1996, 348 (9033) :983-987
[9]   Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study [J].
Gutthann, SP ;
Rodriguez, LAG ;
Castellsague, J ;
Oliart, AD .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 314 (7083) :796-800
[10]   Risk factors for deep vein thrombosis and pulmonary embolism -: A population-based case-control study [J].
Heit, JA ;
Silverstein, MD ;
Mohr, DN ;
Petterson, TM ;
O'Fallon, WM ;
Melton, LJ .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (06) :809-815